Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Certain genetic variants may put bladder cancer patients at increased risk of recurrence

26.03.2014

In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment.

 A new study published in BJU International indicates that inheriting certain DNA sequences can affect a patient's prognosis. The findings may help physicians identify sub-groups of bladder cancer patients who should receive intensive treatment and monitoring.

Nearly half of patients diagnosed with bladder cancer experience tumor recurrences, but it is difficult to predict which patients are at risk. Angeline Andrew, PhD, of the Dartmouth-Hitchcock Norris Cotton Cancer Center in Lebanon, New Hampshire and her colleagues analyzed the genes of 563 patients to identify genetic variants that modify time to bladder cancer recurrence and patient survival.

The investigators isolated DNA from immune cells circulating in the blood, and they examined genes involved in major biological processes linked to cancer: cell death, proliferation, DNA repair, hormone regulation, immune surveillance, and cellular metabolism.

After diagnosis, patients were followed over time to ascertain recurrence and survival status. Patients were followed for a median of 5.4 years, and half of patients experienced at least one recurrence.

The team found that patients with variants in the aldehyde dehydrogenase 2 (ALDH2) gene were likely to experience bladder cancer recurrence shortly after treatment. This gene encodes an enzyme involved in alcohol metabolism.

Time to recurrence was also shorter for patients who had a variant in the vascular cellular adhesion molecule 1 (VCAM1) gene and were treated with immunotherapy. VCAM1 encodes a glycoprotein involved in the development of lymphoid tissues. Patients who had non-invasive tumors and a variant in the DNA repair gene XRCC4 tended to live longer than patients who did not have the variant.

The researchers noted that the novel associations between genetic variants and bladder cancer recurrence uncovered in this study merit future investigation. "The genetic markers that we found could potentially be useful for individually tailoring surveillance and treatment of bladder cancer patients," said Dr. Andrew.

Evelyn Martinez | EurekAlert!
Further information:
http://www.wiley.com

Further reports about: DNA bladder blood cancer genes immune metabolism repair surveillance variants

More articles from Health and Medicine:

nachricht Activity level may predict orthopedic outcomes
23.07.2014 | American Academy of Orthopaedic Surgeons

nachricht New accurate epigenetic test could eliminate unnecessary repeat biopsies for prostate cancer
22.07.2014 | Elsevier Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

“Lens on Life” - Artists and Scientists Explore Cell Divison

08.07.2014 | Event News

First International Conference on Consumer Research | ICCR 2014: Early bird deadline July 31, 2014

08.07.2014 | Event News

First evidence for painless atrial fibrillation treatment

04.07.2014 | Event News

 
Latest News

Enhanced NIST instrument enables high-speed chemical imaging of tissues

23.07.2014 | Life Sciences

Radio frequency ID tags on honey bees reveal hive dynamics

23.07.2014 | Life Sciences

NASA's Aqua Satellite Gets Infrared Hint on Tropical Depression 2

23.07.2014 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>